Matches in SemOpenAlex for { <https://semopenalex.org/work/W62820824> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W62820824 endingPage "53" @default.
- W62820824 startingPage "41" @default.
- W62820824 abstract "Patients with pancreatic cancer usually lack signs and symptoms in the early course of the disease. Even when malignancy is suspected, differential diagnosis between benign and malignant pancreatic disorders may be difficult with current methods. An increasing interest has been focused on the utility of immunological tumour markers. CEA has been widely used since the early seventies, but the results in diagnosis of pancreatic cancer have been disappointing. Tumour marker tests for CA 19-9 and CA 50 are based on monoclonal antibodies to colonic carcinoma cell lines. CA 19-9 and CA 50 are strongly expressed in most tissue specimens from pancreatic carcinomas, but are also found in normal pancreas and benign pancreatic diseases. The CA 19-9 and CA 50 antigens are shed or released into the circulation, and are found in increased concentrations in 70-80% of patients with pancreatic cancer. Also 50-65% of patients with small resectable carcinomas have elevated CA 19-9 and CA 50 levels, although very high serum concentrations usually indicate advanced disease. Slightly elevated serum CA 19-9 and CA 50 levels are seen in some patients with benign pancreatic diseases, more often in acute than in chronic pancreatitis. Elevated values are often observed in patients with benign obstruction of the common bile duct, particularly in patients with cholangitis. In patients with jaundice of hepatocellular origin, the CA 19-9 and CA 50 levels are lower than in extrahepatic cholestasis. CA 19-9 and CA 50 have better diagnostic accuracy for pancreatic cancer than CEA, CA 125, DU-PAN-2, TPA and PSTI/TATI. However, the sensitivities and specificities of CA 19-9 and CA 50 are too low for screening of an asymptomatic population. Nevertheless, CA 19-9 and CA 50 have in our experience shown to be useful complements to other diagnostic methods in symptomatic patients with suspicion of pancreatic cancer. Combinations of different markers improve the sensitivity only slightly compared to the use of CA 19-9 or CA 50 alone. Follow-up using CA 19-9 and CA 50 is a simple and sensitive way of monitoring the postoperative course of patients with pancreatic cancer, and may give a lead time of several months for a recurrence compared to conventional methods." @default.
- W62820824 created "2016-06-24" @default.
- W62820824 creator A5021691968 @default.
- W62820824 creator A5055369999 @default.
- W62820824 creator A5070585559 @default.
- W62820824 date "1989-01-01" @default.
- W62820824 modified "2023-09-23" @default.
- W62820824 title "Tumour markers in pancreatic cancer." @default.
- W62820824 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2667448" @default.
- W62820824 hasPublicationYear "1989" @default.
- W62820824 type Work @default.
- W62820824 sameAs 62820824 @default.
- W62820824 citedByCount "7" @default.
- W62820824 countsByYear W628208242015 @default.
- W62820824 countsByYear W628208242023 @default.
- W62820824 crossrefType "journal-article" @default.
- W62820824 hasAuthorship W62820824A5021691968 @default.
- W62820824 hasAuthorship W62820824A5055369999 @default.
- W62820824 hasAuthorship W62820824A5070585559 @default.
- W62820824 hasConcept C121608353 @default.
- W62820824 hasConcept C126322002 @default.
- W62820824 hasConcept C142724271 @default.
- W62820824 hasConcept C144369459 @default.
- W62820824 hasConcept C2775967933 @default.
- W62820824 hasConcept C2776737053 @default.
- W62820824 hasConcept C2778456037 @default.
- W62820824 hasConcept C2778593092 @default.
- W62820824 hasConcept C2778764654 @default.
- W62820824 hasConcept C2779399171 @default.
- W62820824 hasConcept C2780210213 @default.
- W62820824 hasConcept C2780801072 @default.
- W62820824 hasConcept C2781447364 @default.
- W62820824 hasConcept C71924100 @default.
- W62820824 hasConcept C90924648 @default.
- W62820824 hasConceptScore W62820824C121608353 @default.
- W62820824 hasConceptScore W62820824C126322002 @default.
- W62820824 hasConceptScore W62820824C142724271 @default.
- W62820824 hasConceptScore W62820824C144369459 @default.
- W62820824 hasConceptScore W62820824C2775967933 @default.
- W62820824 hasConceptScore W62820824C2776737053 @default.
- W62820824 hasConceptScore W62820824C2778456037 @default.
- W62820824 hasConceptScore W62820824C2778593092 @default.
- W62820824 hasConceptScore W62820824C2778764654 @default.
- W62820824 hasConceptScore W62820824C2779399171 @default.
- W62820824 hasConceptScore W62820824C2780210213 @default.
- W62820824 hasConceptScore W62820824C2780801072 @default.
- W62820824 hasConceptScore W62820824C2781447364 @default.
- W62820824 hasConceptScore W62820824C71924100 @default.
- W62820824 hasConceptScore W62820824C90924648 @default.
- W62820824 hasIssue "1" @default.
- W62820824 hasLocation W628208241 @default.
- W62820824 hasOpenAccess W62820824 @default.
- W62820824 hasPrimaryLocation W628208241 @default.
- W62820824 hasRelatedWork W1505633768 @default.
- W62820824 hasRelatedWork W1899610622 @default.
- W62820824 hasRelatedWork W1966674147 @default.
- W62820824 hasRelatedWork W2044863052 @default.
- W62820824 hasRelatedWork W2095243983 @default.
- W62820824 hasRelatedWork W2102245227 @default.
- W62820824 hasRelatedWork W2142529597 @default.
- W62820824 hasRelatedWork W2148911532 @default.
- W62820824 hasRelatedWork W2152393478 @default.
- W62820824 hasRelatedWork W2246899291 @default.
- W62820824 hasVolume "78" @default.
- W62820824 isParatext "false" @default.
- W62820824 isRetracted "false" @default.
- W62820824 magId "62820824" @default.
- W62820824 workType "article" @default.